Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Krystal Biotech, Inc. has received an average consensus rating of "Moderate Buy" from brokerages, with one hold rating and six buy ratings. The average twelve-month price target is $209.00.
• Insider trading showed that Suma Krishnan sold 13,435 shares at an average price of $150.30, resulting in a transaction of over $2 million.
• Krystal Biotech reported earnings of $1.29 per share, exceeding analyst expectations, and had a revenue of $96.04 million for the last quarter.

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $209.00.

KRYS has been the topic of several recent research reports. Chardan Capital cut their price target on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Citigroup reissued a "neutral" rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Bank of America lowered their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the sale, the insider owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Crossmark Global Holdings Inc. raised its stake in shares of Krystal Biotech by 2.7% during the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock worth $427,000 after buying an additional 63 shares during the last quarter. Main Management ETF Advisors LLC grew its holdings in Krystal Biotech by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company's stock worth $705,000 after acquiring an additional 84 shares during the period. M&T Bank Corp raised its position in shares of Krystal Biotech by 2.3% during the 2nd quarter. M&T Bank Corp now owns 3,785 shares of the company's stock valued at $520,000 after acquiring an additional 85 shares during the last quarter. Xponance Inc. boosted its position in shares of Krystal Biotech by 4.9% in the 1st quarter. Xponance Inc. now owns 1,873 shares of the company's stock worth $338,000 after purchasing an additional 88 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its position in shares of Krystal Biotech by 6.7% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock worth $273,000 after purchasing an additional 95 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Price Performance

KRYS stock opened at $181.69 on Friday. The firm has a market cap of $5.26 billion, a price-to-earnings ratio of 36.93 and a beta of 0.64. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $207.84. The firm has a fifty day moving average price of $151.72 and a two-hundred day moving average price of $151.49.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.